Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728596 · ClinicalTrials.gov registry record · NA
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
A NA study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- NA
- Development phase
- 3,665
- Enrollment target
NCT02728596: Completed NA study, sponsored by SWOG Cancer Research Network.
NCT02728596 is a NA study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 3,665 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (161% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02728596, a NA study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,665 participants
- Enrollment target
Study Summary
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition that involves fever and a low number of neutrophils (a type of white blood cell) in the blood. Febrile neutropenia increases the risk of infection. Colony stimulating factors are medications sometimes given to patients receiving chemotherapy to prevent febrile neutropenia. Colony stimulating factors are given to patients based on guidelines. Some clinics have an automated system that helps doctors decide when to prescribe them when there is a high risk of developing febrile neutropenia. Gathering information about the use of an automated system to prescribe prophylactic colony stimulating factor may help doctors use colony stimulating factor when it is needed.
Primary Outcome
To compare the use of primary prophylactic colony stimulating factor (PP-CSF) according to recommended clinical practice guidelines among participants registered at intervention components versus usual care components. Primary prophylaxis of CSF (PP-CSF) is defined as the initiation of granulocyte CSFs during the first cycle of myelosuppressive systemic therapy, given 24 to 72 hours after cessation of systemic therapy. Separate mixed effects logistic models will be fit to assess the effect of th
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- OTHER Preventive Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,665 participants |
| Start Date | 2016-10-07 |
| Est. Completion | 2021-08-12 |
| Phase | NA |
What the finished NCT02728596 record still lists
NCT02728596 is an interventional study that assigns participants to a tested intervention. Its 3,665 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (161% higher).
The record links to 0 conditions, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02728596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02728596 about?
NCT02728596 is a clinical study titled "S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)". This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile ...
What is the current status of trial NCT02728596?
This trial is currently completed. It is a NA study. The enrollment target is 3,665 participants. The study started on 2016-10-07. Estimated completion is 2021-08-12.
What interventions are being tested in trial NCT02728596?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Preventive Intervention (OTHER).
Who is sponsoring clinical trial NCT02728596?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02728596's enrollment target sits among peer trials
3,665 36th of 2000 higher than 1,965 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058377 · 3,680 participants · Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- NCT06702553 · 3,650 participants · Phase 3
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
- NCT07249398 · 3,650 participants · NA
Influence of Social Media Ads on Food Choice - Master Protocol
- NCT06784960 · 3,689 participants · NA
Communication Strategies to Increase HPV Vaccination Intention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI